Peli BioThermal Expands Cold Chain Logistics Solutions with Evo Acquisition

Peli BioThermal, recognized for its prowess in temperature-controlled logistics, has recently announced a strategic acquisition of Evo from BioLife Solutions. This move is aimed at broadening their already robust portfolio of logistics solutions, especially within the vital Cell and Gene Therapy sectors.

The Evo portfolio is known for its advanced cryogenic shippers and sophisticated evoIS® technology platform, tailored to meet the demanding needs of the burgeoning Cell and Gene Therapy market. By incorporating Evo into its offerings, Peli BioThermal strengthens its position as a comprehensive provider of cold chain solutions. This acquisition is not only significant for Peli BioThermal but also provides existing and prospective customers with enhanced products and services.

Enhanced Customer Offerings

Through this acquisition, Peli BioThermal will enhance its service delivery to existing customers while simultaneously attracting new clients in the pharmaceutical and biopharmaceutical sectors. The ability to offer an integrated solution across the cold chain logistics spectrum is paramount, particularly in a landscape where precision, reliability, and flexibility are crucial to delivering lifesaving therapies to patients.

Sam Herbert, CEO of Peli BioThermal, emphasized the positive impact of the acquisition, stating, “The addition of Evo is a strategic step forward that rounds out our solutions portfolio and reinforces our commitment to solving our customers' toughest cold chain challenges.” He highlighted that this acquisition offers existing Evo customers the opportunity to benefit from Peli BioThermal’s extensive expertise, further enhancing their operational efficiency.

Integration with Current Technologies

The Evo products will complement Peli BioThermal's existing offerings, which include renowned solutions like the Crēdo™ reusable shippers, NanoCool™ systems, and the recently launched Crēdo Vault™ bulk shipper. This integration allows for more options tailored to customer needs, optimizing for factors such as sustainability, performance, and simplicity in operations. Notably, the Evo products play a pivotal role in the Cell and Gene Therapy market where cryogenic transport is essential.

Implications for the Future

This acquisition marks Peli BioThermal’s second significant addition since its acquisition by Platinum Equity, reflecting the company’s strong momentum in the logistics sector. In a joint statement, Platinum Equity Co-President Jacob Kotzubei and Managing Director Matthew Louie emphasized that integrating Evo into Peli BioThermal’s operations opens avenues for deepening customer relationships and accessing high-growth markets.

The acquisition will see the team and operations from Bruce Township, MI, continue under the Peli BioThermal umbrella, ensuring a seamless transition and continuity in customer support. This alignment is crucial for scaling growth and augmenting the expertise available to customers.

Peli BioThermal stands ready to leverage its global resources to foster growth and innovation, particularly in the critical area of Cell and Gene Therapy logistics. The commitment to enhance and innovate within their portfolio aims to deliver significant value to an expanding customer base.

To learn more about how Peli BioThermal’s enhanced portfolio supports logistics within the Cell and Gene Therapy sector, visit www.pelibiothermal.com.

About Peli BioThermal

As a global leader in temperature-controlled logistics solutions, Peli BioThermal is dedicated to delivering a wide range of both single-use and reusable products and services tailored to the life sciences industry. With a robust reputation for dependability and innovation, Peli BioThermal’s solutions are designed to safeguard life-saving medications throughout their journey in the cold chain.